Stock Track | Autolus Therapeutics Soars 5.65% Pre-Market on Groundbreaking CAR T-Cell Therapy Approval

Stock Track

2024-11-15

Autolus Therapeutics PLC (AUTL) witnessed a significant pre-market surge of 5.65% on Friday, November 15, 2024, driven by positive developments related to its novel CAR T-cell therapy.

According to reports, Autolus Therapeutics recently received regulatory approval for its groundbreaking CAR T-cell therapy, marking a significant achievement in the biotech sector. This regulatory milestone paves the way for the company to commercialize its innovative therapy, which could potentially address unmet medical needs and lead to improved treatment outcomes for patients.

The positive news surrounding Autolus' CAR T-cell therapy approval has generated optimism among investors, who are anticipating the potential commercial success and revenue streams that could arise from the therapy's market launch. The substantial increase in the company's stock price reflects the positive sentiment and expectations surrounding this development.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1144462601"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144462601\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1144462601?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144462601","market":"us","top_or_hot":-1,"title":"Stock Track | Autolus Therapeutics Soars 5.65% Pre-Market on Groundbreaking CAR T-Cell Therapy Approval","media":"Stock Track","content":"<p>Autolus Therapeutics PLC (AUTL) witnessed a significant pre-market surge of 5.65% on Friday, November 15, 2024, driven by positive developments related to its novel CAR T-cell therapy.</p>\n\n<p>According to reports, Autolus Therapeutics recently received regulatory approval for its groundbreaking CAR T-cell therapy, marking a significant achievement in the biotech sector. This regulatory milestone paves the way for the company to commercialize its innovative therapy, which could potentially address unmet medical needs and lead to improved treatment outcomes for patients.</p>\n\n<p>The positive news surrounding Autolus' CAR T-cell therapy approval has generated optimism among investors, who are anticipating the potential commercial success and revenue streams that could arise from the therapy's market launch. The substantial increase in the company's stock price reflects the positive sentiment and expectations surrounding this development.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Autolus Therapeutics Soars 5.65% Pre-Market on Groundbreaking CAR T-Cell Therapy Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Autolus Therapeutics Soars 5.65% Pre-Market on Groundbreaking CAR T-Cell Therapy Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-15 20:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Autolus Therapeutics PLC (AUTL) witnessed a significant pre-market surge of 5.65% on Friday, November 15, 2024, driven by positive developments related to its novel CAR T-cell therapy.</p>\n\n<p>According to reports, Autolus Therapeutics recently received regulatory approval for its groundbreaking CAR T-cell therapy, marking a significant achievement in the biotech sector. This regulatory milestone paves the way for the company to commercialize its innovative therapy, which could potentially address unmet medical needs and lead to improved treatment outcomes for patients.</p>\n\n<p>The positive news surrounding Autolus' CAR T-cell therapy approval has generated optimism among investors, who are anticipating the potential commercial success and revenue streams that could arise from the therapy's market launch. The substantial increase in the company's stock price reflects the positive sentiment and expectations surrounding this development.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUTL","symbol_name":"Autolus Therapeutics PLC","start_time":0,"source_url":"","article_id":"1144462601","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144462601","pubTimestamp":1731673217,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Autolus Therapeutics PLC  witnessed a significant pre-market surge of 5.65% on Friday, November 15, 2024, driven by positive developments related to its novel CAR T-cell therapy.According to reports, Autolus Therapeutics recently received regulatory approval for its groundbreaking CAR T-cell therapy, marking a significant achievement in the biotech sector. This regulatory milestone paves the way for the company to commercialize its innovative therapy, which could potentially address unmet medica","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUTL":"Autolus Therapeutics PLC"},"translate_title":"股票赛道Autolus Therapeutics盘前飙升5.65%，因突破性CAR T细胞疗法获得批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUTL":1},"content_text":"Autolus Therapeutics PLC (AUTL) witnessed a significant pre-market surge of 5.65% on Friday, November 15, 2024, driven by positive developments related to its novel CAR T-cell therapy.\nAccording to reports, Autolus Therapeutics recently received regulatory approval for its groundbreaking CAR T-cell therapy, marking a significant achievement in the biotech sector. This regulatory milestone paves the way for the company to commercialize its innovative therapy, which could potentially address unmet medical needs and lead to improved treatment outcomes for patients.\nThe positive news surrounding Autolus' CAR T-cell therapy approval has generated optimism among investors, who are anticipating the potential commercial success and revenue streams that could arise from the therapy's market launch. The substantial increase in the company's stock price reflects the positive sentiment and expectations surrounding this development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}